Marian A J, Kelly D, Mares A, Fitzgibbons J, Caira T, Hill R, Perryman M B, Roberts R
J Sports Med Phys Fitness. 1994 Mar;34(1):1-10.
Familial hypertrophic cardiomyopathy (FHCM) is an autosomal dominant disease with protean clinical manifestations, ranging from asymptomatic to that of severe heart failure or sudden death. There is no known parameter in individuals with hypertrophic cardiomyopathy (HCM) that predicts a specific clinical event. This is particularly troublesome for premature sudden death that frequently occurs in young athletes without prior symptoms. Recent identification of mutations in the beta myosin heavy chain (beta MHC) gene that co-segregate with the inheritance of the disease provides an opportunity to determine whether certain mutations are more likely to induce a particular clinical event. In this study we analyzed the genotype and phenotype of individuals from two unrelated families with HCM in which the affected individuals have the same missense mutation in exon 13 (G1208A) of the coding sequence for beta MHC.
Individuals from two unrelated families with the diagnosis of FHCM were screened by history, physical examination, electrocardiography, and two dimensional echocardiography. After extraction of DNA from the blood of these individuals, the exon 13 of the beta MHC gene was amplified by polymerase chain reaction (PCR), and the PCR product was digested with Ddel restriction endonuclease. The digestion products were separated by gel electrophoresis and identified by ethidium bromide staining.
We studied 54 individuals from the two families, 21 were affected with HCM of which eleven died prematurely, eight from sudden cardiac death. While most of the nine affected individuals studied had septal hypertrophy, three had concentric hypertrophy and six, left ventricular outflow tract obstruction. Onset of symptoms was in the second decade of life. Electrophoretic separation of the digested DNA (exon 13) from unaffected individuals provided two fragments of 84 and 70 bp in size, as expected. In contrast, DNA from individuals affected with HCM showed four fragments of 84 bp, 70 bp, 52 bp and 32 bp indicating they inherited the mutation. In only one 10 year old male was the mutation present without evidence of HCM which gives an overall penetrance of 86%.
The missense mutation in exon 13 of the beta MHC gene in individuals with FHCM is associated with high penetrance, highly variable expressivity, severe disease, early in onset and a high incidence of premature sudden death. Based on these results we recommend individuals from families with HCM be screened for this missense mutation and if positive, be counselled to avoid combative sports, as it is these activities that often precipitate sudden death.
家族性肥厚型心肌病(FHCM)是一种常染色体显性疾病,临床表现多样,从无症状到严重心力衰竭或猝死。肥厚型心肌病(HCM)患者中尚无已知参数可预测特定临床事件。这对于常在年轻运动员中无先兆症状而频繁发生的猝死尤其棘手。最近发现β肌球蛋白重链(βMHC)基因突变与疾病遗传共分离,这为确定某些突变是否更易引发特定临床事件提供了契机。在本研究中,我们分析了两个无关的HCM家族中个体的基因型和表型,这两个家族中受影响个体在βMHC编码序列的第13外显子(G1208A)有相同的错义突变。
通过病史、体格检查、心电图和二维超声心动图对两个诊断为FHCM的无关家族中的个体进行筛查。从这些个体的血液中提取DNA后,用聚合酶链反应(PCR)扩增βMHC基因的第13外显子,PCR产物用Ddel限制性内切酶消化。消化产物通过凝胶电泳分离,并用溴化乙锭染色鉴定。
我们研究了来自两个家族的54名个体,其中21人患有HCM,其中11人过早死亡,8人死于心源性猝死。在所研究的9名受影响个体中,大多数有室间隔肥厚,3人有向心性肥厚,六人有左心室流出道梗阻。症状出现于生命的第二个十年。未受影响个体消化后的DNA(第13外显子)的电泳分离产生了预期大小的84和70bp的两个片段。相比之下,HCM患者的DNA显示出84bp、70bp、52bp和32bp的四个片段,表明他们遗传了该突变。只有一名10岁男性存在该突变但无HCM证据,总体外显率为86%。
FHCM患者βMHC基因第13外显子的错义突变与高外显率、高度可变的表达性、严重疾病、发病早和过早猝死的高发生率相关。基于这些结果,我们建议对HCM家族中的个体进行该错义突变筛查,如果结果为阳性,建议其避免对抗性运动,因为正是这些活动常常会引发猝死。